First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
Satoshi IgawaTomoya FukuiMasashi KasajimaTaihei OnoTakahiro OzawaMikiko KakegawaSeiichiro KusuharaTakashi SatoYoshiro NakaharaMitsufuji HisashiJiichiro SasakiKatsuhiko NaokiPublished in: Investigational new drugs (2021)
Considering the findings of this study, osimertinib appears to be an effective and safe treatment option for patients with poor PS and advanced NSCLC harboring sensitive EGFR mutations. To obtain conclusive results, further studies with larger cohorts are warranted.